Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1941 2
1944 1
1945 1
1948 1
1951 1
1954 1
1956 1
1957 1
1959 1
1960 2
1961 1
1962 6
1963 7
1964 1
1965 1
1966 2
1967 3
1968 3
1969 5
1970 2
1971 5
1972 13
1973 12
1974 8
1975 5
1976 6
1977 6
1978 11
1979 5
1980 11
1981 14
1982 21
1983 18
1984 23
1985 34
1986 23
1987 28
1988 22
1989 16
1990 26
1991 26
1992 25
1993 34
1994 31
1995 46
1996 48
1997 49
1998 43
1999 57
2000 58
2001 73
2002 124
2003 142
2004 139
2005 166
2006 194
2007 212
2008 206
2009 219
2010 248
2011 301
2012 305
2013 366
2014 381
2015 377
2016 345
2017 343
2018 343
2019 344
2020 393
2021 449
2022 449
2023 120
Text availability
Article attribute
Article type
Publication date

Search Results

6,267 results
Results by year
Filters applied: . Clear all
Page 1
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer.
Lee KM, Lin CC, Servetto A, Bae J, Kandagatla V, Ye D, Kim G, Sudhan DR, Mendiratta S, González Ericsson PI, Balko JM, Lee J, Barnes S, Malladi VS, Tabrizi S, Reddy SM, Yum S, Chang CW, Hutchinson KE, Yost SE, Yuan Y, Chen ZJ, Fu YX, Hanker AB, Arteaga CL. Lee KM, et al. Among authors: lin cc. Cancer Immunol Res. 2022 Jul 1;10(7):829-843. doi: 10.1158/2326-6066.CIR-21-0826. Cancer Immunol Res. 2022. PMID: 35561311 Free PMC article.
Reply.
Lin CC, Kim SJ, Schallhorn JM. Lin CC, et al. Ophthalmology. 2022 Dec;129(12):e159-e160. doi: 10.1016/j.ophtha.2022.08.026. Epub 2022 Sep 28. Ophthalmology. 2022. PMID: 36182589 No abstract available.
The Adverse Effects of Air Pollution on the Eye: A Review.
Lin CC, Chiu CC, Lee PY, Chen KJ, He CX, Hsu SK, Cheng KC. Lin CC, et al. Int J Environ Res Public Health. 2022 Jan 21;19(3):1186. doi: 10.3390/ijerph19031186. Int J Environ Res Public Health. 2022. PMID: 35162209 Free PMC article. Review.
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia.
Xia D, Lianoglou S, Sandmann T, Calvert M, Suh JH, Thomsen E, Dugas J, Pizzo ME, DeVos SL, Earr TK, Lin CC, Davis S, Ha C, Leung AW, Nguyen H, Chau R, Yulyaningsih E, Lopez I, Solanoy H, Masoud ST, Liang CC, Lin K, Astarita G, Khoury N, Zuchero JY, Thorne RG, Shen K, Miller S, Palop JJ, Garceau D, Sasner M, Whitesell JD, Harris JA, Hummel S, Gnörich J, Wind K, Kunze L, Zatcepin A, Brendel M, Willem M, Haass C, Barnett D, Zimmer TS, Orr AG, Scearce-Levie K, Lewcock JW, Di Paolo G, Sanchez PE. Xia D, et al. Among authors: lin cc. Mol Neurodegener. 2022 Jun 11;17(1):41. doi: 10.1186/s13024-022-00547-7. Mol Neurodegener. 2022. PMID: 35690868 Free PMC article.
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
Wang YW, Tsai XC, Hou HA, Tien FM, Liu JH, Chou WC, Ko BS, Chen YW, Lin CC, Cheng CL, Lo MY, Lin YC, Lu LC, Wu SJ, Kuo SH, Hong RL, Huang TC, Yao M. Wang YW, et al. Among authors: lin cc. Ann Hematol. 2022 Feb;101(2):349-358. doi: 10.1007/s00277-021-04711-9. Epub 2021 Nov 11. Ann Hematol. 2022. PMID: 34766217 Clinical Trial.
Lirentelimab for severe and chronic forms of allergic conjunctivitis.
Anesi SD, Tauber J, Nguyen QD, Chang P, Berdy GJ, Lin CC, Chu DS, Levine HT, Fernandez AD, Roy N, Asbell PA, Kantor AM, Chang AT, Singh B, Youngblood BA, Jeng BH, Jhanji V, Rasmussen HS, Foster CS. Anesi SD, et al. Among authors: lin cc. J Allergy Clin Immunol. 2022 Sep;150(3):631-639. doi: 10.1016/j.jaci.2022.03.021. Epub 2022 Apr 4. J Allergy Clin Immunol. 2022. PMID: 35390403 Free article. Clinical Trial.
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.
Abdul Razak AR, Bauer S, Suarez C, Lin CC, Quek R, Hütter-Krönke ML, Cubedo R, Ferretti S, Guerreiro N, Jullion A, Orlando EJ, Clementi G, Sand Dejmek J, Halilovic E, Fabre C, Blay JY, Italiano A. Abdul Razak AR, et al. Among authors: lin cc. Clin Cancer Res. 2022 Mar 15;28(6):1087-1097. doi: 10.1158/1078-0432.CCR-21-1291. Clin Cancer Res. 2022. PMID: 34921024 Clinical Trial.
6,267 results